

konzept

Thinking
outside the box

■ about

Tilman M. Brotz, Ph.D.
Principal Consultant

tilmann@konzept.us

[www.linkedin.com/
in/tilmannbrotz](http://www.linkedin.com/in/tilmannbrotz)

+1.510.220.5713

www.konzept.us

Dr. Brotz is a drug discovery and development consultant working with early stage biotech companies and investment funds on drug development strategy, R&D operations and due diligence projects. He has 20 years of research experience with over 10 years in the biopharmaceutical industry, where he led small molecule development from discovery through Phase 2 Proof of Concept. Having fostered a strong entrepreneurial spirit during his career in small company environments, Dr. Brotz is uniquely positioned to understand and address the specific challenges and needs of his clients.

■ services

Development Sciences

Drug development strategy from discovery through Proof of Concept | Efficacy Models, Toxicology, DMPK | Regulatory document drafting & review | Translational research | Clinical & preclinical exploratory data analysis

R&D Operations

Implementation of virtual R&D operations | Project management, timelines, budgets | CRO selection, qualification & management | Study management, protocol review | Due diligence

■ experience & expertise

Dr. Brotz's work experience spans the public and private biomedical research sector holding positions of increasing responsibilities at the National Cancer Institute and Renovis. Most recently he was Vice President, Preclinical Research & Development at VIA Pharmaceuticals, a virtual biopharmaceutical company where he, among other projects, repurposed an asthma drug for atherosclerosis. He has worked in several therapeutic areas including cardiovascular and metabolic diseases, autoimmune diseases, neurodegeneration, CNS trauma and pain. His technical expertise covers toxicology, pharmacology, DMPK, CMC & regulatory affairs as well as translational research and biomarker validation. He creates efficient development plans with realistic budgets and timelines in resource constrained environments and has an extensive track record managing large portfolios of CROs, CMOs & consultants. He was a member on numerous in-licensing, out-licensing and due-diligence teams leading to successful in-licensing deals and global alliances. He has contributed to many INDs incl. 505(b)(2) filings and interacted with regulatory agencies in teleconferences, pre-IND meetings and End-of-Phase 2a meetings. Enjoying the fast paced culture in start-up and small cap companies, he is well versed in managing change in dynamic environments. Dr. Brotz received his Ph.D. in animal physiology/neuroscience from the University of Tübingen and completed his postdoctoral training in developmental neuroscience at the University of California, Berkeley.

Drug Development Consulting